Skip to main content
Clinical Trials/CTRI/2017/08/009204
CTRI/2017/08/009204
Not yet recruiting
Phase 3

A prospective, randomized, two arm, singleblind, parallel, active controlled, multicentre,phase III clinical study to evaluate theimmunogenicity and safety of InactivatedInfluenza vaccine (split virion) I.P.(Tetravalent) of M/s Cadila HealthcareLimited in healthy children aged 6 months to17 years

Cadila Healthcare Ltd0 sites0 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Health Condition 1: Z23- Encounter for immunization
Sponsor
Cadila Healthcare Ltd
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Healthy subject of either gender 6 months to 17 years of age
  • 2\. Written informed consent from subjectâ??s either parent (mother / father) and
  • written assent from subjects more than 7 years of age
  • 3\. Subjectâ??s either parent (mother / father) literate enough to fill the diary card

Exclusion Criteria

  • 1\. Past history of hypersensitivity reaction, neurological disorder (Guillainâ??Barré
  • syndrome or others) or any serious adverse event to any vaccine, egg,
  • chicken proteins, aminoglycoside antibiotics
  • 2\. Subjects with history of administration of any influenza vaccine or subjects
  • with laboratory confirmed influenza in past
  • 3\. Subjects with thrombocytopenia or any coagulation disorder, or subjects on
  • anticoagulation therapy
  • 4\. Subjects with confirmed or suspected immunosuppressive or
  • immunodeficiency disorder; or subjects on any immunosuppressive or
  • immunostimulant therapy

Outcomes

Primary Outcomes

Not specified

Similar Trials